Celebrating 25 years Est 1999-2024
*Across 3 years $2158.56 only $755.50
Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3...
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication...
November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology...
$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on...
October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology...
Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa...
ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod...
August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
$478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo...
July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent...
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse...
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory...
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and...
June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.